Thibault Moreau
Thibault Moreau is an expert in Neurology at Centre Hospitalier Universitaire Dijon Bourgogne (France). As of October 2026, ScienceLeadR ranks Thibault Moreau in the top 1% of experts worldwide for Multiple Sclerosis and Autoimmune Diseases. Thibault Moreau has authored 429 publications, the most recent in 2026, and is an investigator in 31 clinical trials, 6 of them ongoing. SLR score: 1,236 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Immunology - Psychiatry - Neurosurgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1988 - 2026
Number : 429
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Episodic memory deficits are associated with social cognitive impairments in multiple sclerosis. PMID 42622682 — sclerosis, multiple sclerosis, executive function, cognitive dysfunction, neurosurgery, cognition disorders, memory, neurology, cognition, memory, episodic | J Neurol | 2026 | 0 |
| Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. PMID 42161588 — registries, sclerosis, multiple sclerosis, natalizumab, alemtuzumab, multiple chronic conditions, cohort studies, therapeutics, neurology | J Neurol Neurosurg Psychiatry | 2026 | 0 |
| Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative study. PMID 42091137 — research design, sclerosis, multiple sclerosis, oligoclonal bands, algorithms, demyelinating diseases, diagnosis | Mult Scler | 2026 | 0 |
| Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis. PMID 42085644 — registries, sclerosis, multiple sclerosis, probability, therapeutics, neurology, multiple sclerosis, relapsing-remitting | Neurology | 2026 | 0 |
| Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study. PMID 41935174 — sclerosis, multiple sclerosis, cohort studies, therapeutics | CNS Drugs | 2026 | 0 |
Clinical Studies 31
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 14
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis followed by long term treatment with remibrutinib 2023-509372-41-00 — sclerosis, multiple sclerosis, safety, therapeutics | Phase 3 | Active not recruiting | 2022 |
| DESIRE MS A prospective randomized non inferiority trial comparing anti CD20 maintenance versus De Escalation Strategy In Relapsing Remitting Multiple Sclerosis 2024-513292-40-00 — sclerosis, multiple sclerosis, maintenance, therapeutics, random allocation, multiple sclerosis, relapsing-remitting | Phase 3 | Recruiting | 2026 |
| PRIMUS Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis NCT07647952 — sclerosis, multiple sclerosis, multiple chronic conditions, decision support systems, clinical, therapeutics, software, multiple sclerosis, relapsing-remitting, medical devices | N/A | Not yet recruiting | 2026 |
| Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence Myth or Reality NCT07545889 — injections, cells, sclerosis, multiple sclerosis, staphylococcal protein a, nitrites, spinal cord, blood, absenteeism, glial fibrillary acidic protein, neuropsychological tests, stress, physiological, brain, conversion disorder, cell-free nucleic acids, biomarkers, signs and symptoms, urinalysis, leukocytes, diagnosis, nervous system diseases, wounds and injuries, dna, multiple sclerosis, relapsing-remitting, infections, prospective studies, spine | N/A | Not yet recruiting | 2026 |
| Disease Modifying Therapies Withdrawal in Inactive Relapsing remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS Therapies Withdrawal IN Relapsing Multiple Sclerosis) NCT06663189 — glatiramer acetate, depression, sclerosis, multiple sclerosis, quality of life, spinal cord, disability evaluation, dimethyl fumarate, acetates, aged, fumarates, therapeutics, random allocation, multiple sclerosis, relapsing-remitting, infections, spine | Phase 3 | Not yet recruiting | 2025 |
LeadR Networks
Main global connection map